Stockscreener 앱 받기
2.49
8.26%
0.19
시간 외 거래:
2.49
전일 마감가:
$2.30
열려 있는:
$2.27
하루 거래량:
1.63M
Relative Volume:
0.90
시가총액:
$447.51M
수익:
$109.16M
순이익/손실:
$-9.57M
주가수익비율:
-23.67
EPS:
-0.1052
순현금흐름:
$-104.72M
1주 성능:
-0.40%
1개월 성능:
+16.36%
6개월 성능:
+421.79%
1년 성능:
+327.10%
1일 변동 폭
$2.25
$2.545
1주일 범위
$2.2304
$2.58
52주 변동 폭
$0.3418
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
명칭
Century Therapeutics Inc
전화
215-981-4000
주소
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.49 | 413.36M | 109.16M | -9.57M | -104.72M | -0.1052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | TD Cowen | Buy |
| 2024-08-08 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 개시 | Chardan Capital Markets | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-05-23 | 개시 | H.C. Wainwright | Buy |
| 2022-05-12 | 개시 | William Blair | Mkt Perform |
| 2021-07-13 | 개시 | BofA Securities | Buy |
| 2021-07-13 | 개시 | JP Morgan | Overweight |
| 2021-07-13 | 개시 | Piper Sandler | Overweight |
모두보기
Century Therapeutics Inc 주식(IPSC)의 최신 뉴스
Dip Buying: How sensitive is Century Therapeutics Inc to inflationQuarterly Market Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline - MyChesCo
Century Therapeutics Hits New 52-Week High at $2.95 - Markets Mojo
Century Therapeutics Hits New 52-Week High of $3.04 Amid Market Fluctuations - Markets Mojo
Century Therapeutics (NASDAQ:IPSC) Insider Sells $25,693.80 in Stock - MarketBeat
Century Therapeutics (NASDAQ:IPSC) SVP Sells $17,959.65 in Stock - MarketBeat
Century Therapeutics (IPSC) SVP sells 7,043 shares to cover tax withholding - Stock Titan
Century Therapeutics (IPSC) officer sells shares to cover tax - Stock Titan
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Growth in Short Interest - MarketBeat
Zacks Research Downgrades Century Therapeutics (NASDAQ:IPSC) to Hold - MarketBeat
Century Therapeutics (IPSC) CEO has 55,397 shares withheld for RSU taxes - Stock Titan
Century Therapeutics (IPSC) CSO has 1,431 shares withheld for RSU tax obligations - Stock Titan
Century Therapeutics (IPSC) Receives a Buy from Clear Street - The Globe and Mail
Century Therapeutics (NASDAQ:IPSC) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Lantheus (LNTH), Century Therapeutics (IPSC) - The Globe and Mail
Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives - Sahm
IPSC (NASDAQ: IPSC) plans sale of 10,076 vested shares via Fidelity - Stock Titan
Century Therapeutics, Inc. announced that it has received $134.997458 million in funding from a group of investors - marketscreener.com
Century Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Century Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Century Therapeutics Reports 2025 Results and Pipeline Progress - TipRanks
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates - Investing News Network
CENTURY THERAPEUTICS ($IPSC) Releases Q4 2025 Earnings - Quiver Quantitative
Century Therapeutics 10-K Summary — Revenue: $— | EPS: $— - TradingView
Century Therapeutics 2025 net loss narrows beating estimates - TradingView
Century Therapeutics (NASDAQ: IPSC) slashes 2025 net loss on $109M revenue - Stock Titan
BRIEF-Century Therapeutics FY Net Income USD -9.58 Million - TradingView
Biotech tests cell therapy as type 1 diabetes cure, eyes 2027 data - Stock Titan
Bearish Setup: Is Century Therapeutics Inc undervalued by DCF analysis2026 Catalysts & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Century Therapeutics (IPSC) officer auto-sells shares to cover RSU tax - Stock Titan
Century Therapeutics (IPSC) SVP Carr auto-sells shares to cover RSU tax - Stock Titan
Century Therapeutics (IPSC) to Release Quarterly Earnings on Wednesday - MarketBeat
Century Therapeutics (IPSC) CEO reports 463-share tax withholding on RSU vesting - Stock Titan
[144] Century Therapeutics, Inc. SEC Filing - Stock Titan
Century Therapeutics (NASDAQ:IPSC) Raised to "Hold" at Wall Street Zen - MarketBeat
Piper Sandler highlights Century Therapeutics (IPSC) cash runway through 2029, upcoming IND submission - MSN
Century Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual Meeting - MSN
IPSC Financials: Income Statement, Balance Sheet & Cash Flow | Century Therapeutics, Inc. - Stock Titan
Should I buy Century Therapeutics Inc stock nowJuly 2025 Final Week & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 39.8% in February - MarketBeat
IPSC SEC FilingsCentury Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Closing: How does Century Therapeutics Inc perform in inflationary periodsDollar Strength & Entry Point Confirmation Signals - baoquankhu1.vn
Century Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Century Therapeutics (NASDAQ:IPSC) Coverage Initiated by Analysts at TD Cowen - Defense World
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Century Therapeutics (IPSC) - The Globe and Mail
Movement Recap: Is Century Therapeutics Inc forming a bullish divergenceQuarterly Portfolio Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Century Therapeutics to Participate in Upcoming Investor Conferences in March - Investing News Network
Century Therapeutics (NASDAQ:IPSC) Now Covered by Analysts at TD Cowen - MarketBeat
TD Cowen Initiates Century Therapeutics at Buy - marketscreener.com
TD Cowen initiates Century Therapeutics stock rating at Buy - Investing.com Australia
Century Therapeutics Inc (IPSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):